<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38932128</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>24</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Efficient Production of Enterovirus 71 (EV71) Virus-like Particles by Controlling Promoter Strength in Insect Cells.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">834</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16060834</ELocationID><Abstract><AbstractText>This study was conducted to efficiently produce virus-like particles (VLPs) of enterovirus 71 (EV71), a causative virus of hand, foot, and mouth disease (HFMD). The expression level of the P1 precursor, a structural protein of EV71, was modified to increase VLP production, and the optimal expression level and duration of the 3CD protein for P1 cleavage were determined. The expression level and duration of 3CD were controlled by the <i>p10</i> promoter, which was weakened by repeated burst sequence (BS) applications, as well as the <i>OpIE2</i> promoter, which was weakened by the insertion of random untranslated region sequences of various lengths. The cleavage and production efficiency of the P1 precursor were compared based on the expression time and level of 3CD, revealing that the <i>p10</i>-BS5 promoter with four repeated BSs was the most effective. When P1 and 3CD were expressed using the hyperexpression vector and the <i>p10</i>-BS5 promoter, high levels of structural protein production and normal HFMD-VLP formation were observed, respectively. This study suggests that the production efficiency of HFMD-VLPs can be significantly enhanced by increasing the expression of the P1 precursor and controlling the amount and duration of 3CD expression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyun-Soo</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Department of Agricultural Biology, College of Agriculture, Life &amp; Environment Science, Chungbuk National University, Cheongju 28644, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moon</LastName><ForeName>Hyuk-Jin</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Agricultural Biology, College of Agriculture, Life &amp; Environment Science, Chungbuk National University, Cheongju 28644, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Jae-Bang</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Optipharm Inc., Osong 28158, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Beom-Ku</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>Optipharm Inc., Osong 28158, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woo</LastName><ForeName>Soo Dong</ForeName><Initials>SD</Initials><Identifier Source="ORCID">0000-0002-3739-4264</Identifier><AffiliationInfo><Affiliation>Department of Agricultural Biology, College of Agriculture, Life &amp; Environment Science, Chungbuk National University, Cheongju 28644, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HV23C0132</GrantID><Agency>Ministry of Health &amp; Welfare, Republic of Korea</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D011401" MajorTopicYN="Y">Promoter Regions, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061987" MajorTopicYN="N">Sf9 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HFMD</Keyword><Keyword MajorTopicYN="N">VLP</Keyword><Keyword MajorTopicYN="N">baculovirus</Keyword><Keyword MajorTopicYN="N">burst sequences</Keyword><Keyword MajorTopicYN="N">enterovirus 71</Keyword></KeywordList><CoiStatement>Author Jae-Bang Choi and Beom-Ku Han were employed by the company Optipharm Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>1</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38932128</ArticleId><ArticleId IdType="pmc">PMC11209064</ArticleId><ArticleId IdType="doi">10.3390/v16060834</ArticleId><ArticleId IdType="pii">v16060834</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chong P.C.S., Klein M. Enterovirus 71. In: Plotkin S.A., Orenstein W.A., Offit P.A., Edwards K.M., editors. Plotkin’s Vaccines. 7th ed. Elsevier; Amsterdam, The Netherlands: 2018. pp. 288–294.e3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-323-35761-6.00021-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai K., Wang Y., Guo Z., Yu H., Li H., Zhang L., Xu S., Zhang Q. Clinical characteristics and managements of severe hand, foot and mouth disease caused by enterovirus A71 and coxsackievirus A16 in Shanghai, China. BMC Infect. Dis. 2019;19:285. doi: 10.1186/s12879-019-3878-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-019-3878-6</ArticleId><ArticleId IdType="pmc">PMC6438032</ArticleId><ArticleId IdType="pubmed">30917800</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu W., Li B., Xie T. Children with severe enterovirus A71 infection. BMC Pediatr. 2023;23:172. doi: 10.1186/s12887-023-03980-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12887-023-03980-9</ArticleId><ArticleId IdType="pmc">PMC10100469</ArticleId><ArticleId IdType="pubmed">37055743</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M.L., Shih S.R., Tolbert B.S., Brewer G. Enterovirus A71 Vaccines. Vaccines. 2021;9:199. doi: 10.3390/vaccines9030199.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9030199</ArticleId><ArticleId IdType="pmc">PMC7997495</ArticleId><ArticleId IdType="pubmed">33673595</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D., Lu J., Lu J. Enterovirus 71 vaccine: Close but still far. Int. J. Infect. Dis. 2010;14:e739–e743. doi: 10.1016/j.ijid.2009.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2009.12.002</ArticleId><ArticleId IdType="pmc">PMC7110504</ArticleId><ArticleId IdType="pubmed">20400350</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding X., Liu D., Booth G., Gao W., Lu Y. Virus-like particle engineering: From rational design to versatile applications. Biotechnol. J. 2018;13:e1700324. doi: 10.1002/biot.201700324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biot.201700324</ArticleId><ArticleId IdType="pubmed">29453861</ArticleId></ArticleIdList></Reference><Reference><Citation>Nooraei S., Bahrulolum H., Hoseini Z.S., Katalani C., Hajizade A., Easton A.J., Ahmadian G. Virus-like particles: Preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J. Nanobiotechnol. 2021;19:59. doi: 10.1186/s12951-021-00806-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12951-021-00806-7</ArticleId><ArticleId IdType="pmc">PMC7905985</ArticleId><ArticleId IdType="pubmed">33632278</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachmann M.F., Jennings G.T. Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 2010;10:787–796. doi: 10.1038/nri2868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2868</ArticleId><ArticleId IdType="pubmed">20948547</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicente T., Roldão A., Peixoto C., Carrondo M.J.T., Alves P.M. Large-scale production and purification of VLP-based vaccines. J. Invertebr. Pathol. 2011;107:S42–S48. doi: 10.1016/j.jip.2011.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jip.2011.05.004</ArticleId><ArticleId IdType="pmc">PMC7094596</ArticleId><ArticleId IdType="pubmed">21784230</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopal R., Schneemann A. Production and application of insect virus-based VLPs. Methods Mol. Biol. 2018;1776:125–141. doi: 10.1007/978-1-4939-7808-3_8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-7808-3_8</ArticleId><ArticleId IdType="pubmed">29869238</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaji H. Suitability and perspectives on using recombinant insect cells for the production of virus-like particles. Appl. Microbiol. Biotechnol. 2014;98:1963–1970. doi: 10.1007/s00253-013-5474-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00253-013-5474-9</ArticleId><ArticleId IdType="pubmed">24407451</ArticleId></ArticleIdList></Reference><Reference><Citation>Somasundaram B., Lua L.H.L. Development of picornavirus-like particle vaccines. Pharm. Bioprocess. 2015;3:45–59. doi: 10.4155/pbp.14.39.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/pbp.14.39</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J., Liu H., Qu M., Hou A., Zhou Y., Sun B., Cai L., Gao F., Su W., Jiang C. Determination of the cleavage site of enterovirus 71 VP0 and the effect of this cleavage on viral infectivity and assembly. Microb. Pathog. 2019;134:103568. doi: 10.1016/j.micpath.2019.103568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2019.103568</ArticleId><ArticleId IdType="pubmed">31195113</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung Y.C., Huang J.H., Lai C.W., Sheng H.C., Shih S.R., Ho M.S., Hu Y.C. Expression, purification and characterization of enterovirus-71 virus-like particles. World J. Gastroenterol. 2006;12:921–927. doi: 10.3748/wjg.v12.i6.921.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v12.i6.921</ArticleId><ArticleId IdType="pmc">PMC4066158</ArticleId><ArticleId IdType="pubmed">16521221</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y.C., Hsu J.T., Huang J.H., Ho M.S., Ho Y.C. Formation of enterovirus-like particle aggregates by recombinant baculoviruses co-expressing P1 and 3CD in insect cells. Biotechnol. Lett. 2003;25:919–925. doi: 10.1023/a:1024071514438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/a:1024071514438</ArticleId><ArticleId IdType="pubmed">12889824</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S.Y., Yeh C.T., Li W.H., Yu C.P., Lin W.C., Yang J.Y., Wu H.L., Hu Y.C. Enhanced enterovirus 71 virus-like particle yield from a new baculovirus design. Biotechnol. Bioeng. 2015;112:2005–2015. doi: 10.1002/bit.25625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bit.25625</ArticleId><ArticleId IdType="pmc">PMC7161748</ArticleId><ArticleId IdType="pubmed">25997678</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung C.Y., Chen C.Y., Lin S.Y., Chung Y.C., Chiu H.Y., Chi W.K., Lin Y.L., Chiang B.L., Chen W.J., Hu Y.C. Enterovirus 71 virus-like particle vaccine: Improved production conditions for enhanced yield. Vaccine. 2010;28:6951–6957. doi: 10.1016/j.vaccine.2010.08.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.08.052</ArticleId><ArticleId IdType="pubmed">20797455</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.J., Son H.S., Lee S.W., Yoon Y., Hyeon J.Y., Chung G.T., Lee J.W., Yoo J.S. Efficient expression of enterovirus 71 based on virus-like particles vaccine. PLoS ONE. 2019;14:e0210477. doi: 10.1371/journal.pone.0210477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0210477</ArticleId><ArticleId IdType="pmc">PMC6405078</ArticleId><ArticleId IdType="pubmed">30845175</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruder M.R., Aucoin M.G. Utility of aternative promoters for foreign gene expression using the baculovirus expression vector system. Viruses. 2022;14:2670. doi: 10.3390/v14122670.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14122670</ArticleId><ArticleId IdType="pmc">PMC9786725</ArticleId><ArticleId IdType="pubmed">36560674</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.H., Gwak W.S., Bae S.M., Choi J.B., Han B.K., Woo S.D. Increased productivity of the baculovirus expression vector system by combining enhancing factors. J. Asia-Pac. Entomol. 2018;21:1079–1084. doi: 10.1016/j.aspen.2018.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aspen.2018.08.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwak W.S., Kim H.S., Bae J.S., Kim T.H., Bae S.M., Woo S.D. Development of a novel enhanced baculovirus expression vector via promoter combination. J. Asia-Pac. Entomol. 2020;23:909–914. doi: 10.1016/j.aspen.2020.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aspen.2020.07.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.S., Gwak W.S., Bae J.S., Kim T.H., Choi J.B., Han B.K., Woo S.D. Effects of repeated burst sequences on the p10 promoter activity of Bombyx mori nucleopolyhedrovirus. J. Asia-Pac. Entomol. 2021;24:7–13. doi: 10.1016/j.aspen.2021.04.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aspen.2021.04.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitchman R.B., Locanto E., Possee R.D., King L.A. Optimizing the baculovirus expression vector system. Methods. 2011;55:52–57. doi: 10.1016/j.ymeth.2011.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2011.06.011</ArticleId><ArticleId IdType="pubmed">21945427</ArticleId></ArticleIdList></Reference><Reference><Citation>Manohar S.L., Kanamasa S., Nishina T., Kato T., Park E.Y. Enhanced gene expression in insect cells and silkworm larva by modified polyhedrin promoter using repeated burst sequence and very late transcriptional factor-1. Biotechnol. Bioeng. 2010;107:909–916. doi: 10.1002/bit.22896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bit.22896</ArticleId><ArticleId IdType="pubmed">20717974</ArticleId></ArticleIdList></Reference><Reference><Citation>Turchinovich A., Surowy H.M., Tonevitsky A.G., Burwinkel B. Interference in transcription of overexpressed genes by promoter-proximal downstream sequences. Sci. Rep. 2016;6:30735. doi: 10.1038/srep30735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep30735</ArticleId><ArticleId IdType="pmc">PMC4971500</ArticleId><ArticleId IdType="pubmed">27485701</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Ku Z., Zhang X., Ye X., Chen J., Liu Q., Zhang W., Zhang C., Fu Z., Jin X., et al. Structure, immunogenicity, and protective mechanism of an engineered Enterovirus 71-like particle vaccine mimicking 80S empty capsid. J. Virol. 2017;92:e01330-17. doi: 10.1128/jvi.01330-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01330-17</ArticleId><ArticleId IdType="pmc">PMC5730765</ArticleId><ArticleId IdType="pubmed">29070691</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>